Chemical Formula: C18H25N3O3
Chemical Formula C18H25N3O3
Found 11 metabolite its formula value is C18H25N3O3
5-hydroxy saxagliptin
5-hydroxy saxagliptin is a metabolite of saxagliptin. Saxagliptin, previously identified as BMS-477118, is a new oral hypoglycemic of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. (Wikipedia)
TERT-BUTYL 4-(3-METHYL-2-OXO-2,3-DIHYDRO-1H-BENZO[D]IMIDAZOL-1-YL)PIPERIDINE-1-CARBOXYLATE
Hydroxy Saxagliptin
D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
1-[1-[2-[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]ethyl]piperidin-4-yl]imidazolidin-2-one
N-{5-ethyl-1-[2-(morpholin-4-yl)ethyl]-2-oxo-2,3-dihydro-1H-indol-3-yl}acetamide
2-(2-Hydroxyethoxy)-N-(2-diethylaminoethyl)-4-quinolinecarboxamide
2-(3-Hydroxybutoxy)-N-[2-(ethylamino)ethyl]-4-quinolinecarboxamide
2-(3-Hydroxybutoxy)-N-(2-(dimethylamino)ethyl)-4-quinolinecarboxamide
Acid Ceramidase-IN-1
Acid Ceramidase-IN-1 is a potent and oral bioavailable acid ceramidase (AC, ASAH-1) inhibitor (hAC IC50=0.166 μM). Acid Ceramidase-IN-1 has excellent brain penetration in mice[1].